Tempus AI: The Investment Opportunity Of A Decade, Strong Buy
Tempus AI's financials have significantly improved, with positive cash flow expected next quarter. Read why TEM stock is a ...
CRISPR Therapeutics: An Uninspiring Start For Casgevy
CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...
Jim Cramer on Illumina (ILMN): ‘A Challenged Company’ That He Doesn’t Prefer
We recently published a list of Jim Cramer’s Latest Lightning Round: 7 Stocks in Focus. In this article, we are going to take ...
Jim Cramer Says Illumina Is 'Challenged,' Recommends Selling This Industrial Stock
Cramer looks at Illumina, Archer Aviation, NANO Nuclear Energy, Steris, Sixth Street Specialty Lending, Lam Research and ...
Illumina Inc. stock rises Friday, still underperforms market
The stock's rise snapped a four-day losing streak.
ETF Daily News5d
Royal Bank of Canada Cuts Illumina (NASDAQ:ILMN) Price Target to $128.00
They currently have an outperform rating on the life sciences company’s stock. ILMN has been the topic of a number of other reports. Guggenheim cut their price objective on Illumina from $170.00 ...
JD Supra5d
The Illumina Ban and What It Means for Life Science Companies
Amid increasing economic tensions with the United States, China recently announced that it would ban Illumina, a U.S.-based company and the ...